FRAMINGHAM, Mass., April 10, 2015 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced it will webcast two events at the 35th International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting and Scientific Sessions in Nice, France on Thursday, April 16, 2015.
Investor Breakout Session
HeartWare CEO Doug Godshall will host an investor breakout session at 3:00 p.m. local time (9:00 a.m. U.S. Eastern Time) on April 16, 2015. A live webcast of HeartWare's investor meeting will be available to the public at http://edge.media-server.com/m/p/efpikrgn and through the investor section of the company's website at www.heartware.com. A replay of the webcast will be available through the above weblink shortly following completion of the call.
HeartWare ISHLT Symposium
HeartWare will host a lunch symposium titled, "Deeper Dive into HeartWare Clinical and Real-World Results," on Thursday, April 16, 2015 from 12:45 p.m. to 2:15 p.m. local time (6:45 a.m. to 8:15 a.m. U.S. Eastern Time). The meeting will be held in the Clio/Thalie room at the Acropolis Congress Center. Clinicians from the U.S. and Europe will highlight clinical and commercial experience with the HeartWare System, including discussions of the oral presentations detailed below.
An audio feed of the symposium will be available to the public via webcast at http://edge.media-server.com/m/p/fwekfebu and through the investor section of the company's website at www.heartware.com. A replay of the webcast will be available through the above weblink shortly following completion of the call.
Select Oral Presentations at ISHLT on April 16 (all times local):
HeartWare HVAD for the Treatment of Patients with Advanced Heart Failure Ineligible for Cardiac Transplantation: Results of the ENDURANCE Destination Therapy Trial (Pagani)
Thursday, April 16 at 9:50 am
Long Term Support of Patients Receiving an LVAD for Advanced Heart Failure: A Subgroup Analysis of the Registry to Evaluate the HeartWare® Left Ventricular Assist System (The REVOLVE Registry) (Schmitto)
Thursday, April 16 at 11:00 am
The HeartWare HVAD Pump in Clinical Practice - Results from 1,035 Patients Analyzed in a Retrospective European Multi-Center Study (Krabatsch)
Thursday, April 16; at 11:45 am
Neurological Events in Patients Bridged with Long-Term Mechanical Circulatory Support: A Device Specific Comparative Analysis (Maltais)
Thursday, April 16; at 4:30 pm
About HeartWare International
HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-support circulatory assist device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. The HeartWare System is approved in the United States for the intended use as a bridge to cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure, has received CE Marking in the European Union and has been used to treat patients in 41 countries. The device is also currently the subject of a U.S. clinical trial for destination therapy. For additional information, please visit the Company's website at www.heartware.com.
For additional information:
HeartWare International, Inc.
Phone: +1 508 739 0864
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/heartware-announces-webcasts-at-the-35th-international-society-for-heart-and-lung-transplantation-annual-meeting-300064348.html
SOURCE HeartWare International, Inc.